AUPH Earnings Date: Nov 3, 2026 (Estimated) — Aurinia Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is AUPH's next earnings date?
Aurinia Pharmaceuticals Inc. (AUPH) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.22 on revenue of $83.6M.
How did AUPH do in its last earnings report?
In its most recent report on Oct 30, 2026, Aurinia Pharmaceuticals Inc. posted EPS of $0.23 versus the $0.22 estimate, a beat of 4.5%. Revenue was $83.7M against a $83.6M estimate.
How much does AUPH stock move after earnings?
AUPH beat EPS estimates in 7 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 6.1% (up or down) in the day after earnings.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
🤖 AI Earnings Analysis
Aurinia’s $84M revenue and $0.23 EPS modestly beat estimates, with $31M operating income signaling strong profitability; however, extraordinary growth rates likely reflect a low comparison base, tempering the apparent acceleration.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | 0.22 | 0.23 | +4.55% | $83.7M | ✅ Beat | — | — | — | |
| 2026-08-06 | Q2 2026 | 0.24 | 0.28 | +16.67% | $83.2M | ✅ Beat | +6.19% | +1.71% | +6.12% |
| 2026-05-07 | Q1 2026 | 0.19 | 0.25 | +31.58% | $77.7M | ✅ Beat | -6.80% | -1.32% | -2.49% |
| 2026-02-26 | Q4 2025 | 0.21 | 0.26 | +23.81% | $77.1M | ✅ Beat | -3.19% | +4.23% | +1.18% |
| 2025-11-04 | Q3 2025 | 0.16 | 0.23 | +43.75% | $73.5M | ✅ Beat | +8.35% | +13.06% | +13.21% |
| 2025-07-31 | Q2 2025 | 0.16 | 0.16 | +0.00% | $70.0M | ➖ Inline | +2.15% | +28.29% | +33.48% |
| 2025-02-27 | Q4 2024 | -0.02 | 0.01 | +150.00% | $59.9M | ✅ Beat | -5.03% | +9.06% | +6.42% |
| 2024-11-07 | Q3 2024 | 0.01 | 0.10 | +900.00% | $67.8M | ✅ Beat | +10.90% | +10.11% | +18.75% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $83.7M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 94.9% | $79.4M | +12.4% | $60.0M | $66.6M | $70.6M | $74.2M |
| License, Collaboration and Royalty Revenue | 5.1% | $4.3M | +50.7% | $2.5M | $3.4M | $2.8M | $2.9M |
By region
FY2025 · $283.1M total · annual
| Segment | Share | Revenue | YoY | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 93.2% | $263.8M | +25.6% | $200K | — | $45.5M | $102.5M |
| JAPAN | 6.8% | $19.2M | -23.3% | — | $50.0M | — | $31.5M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.